Skip to main content

Table 1 Patient and Lesion Characteristics

From: Immune checkpoint inhibition in patients treated with stereotactic radiation for brain metastases

Variables by patient SRS alone (%) N = 143 SRS-ICI (%) N = 36 P-value
Median Follow up (q1, q3) 10.3 (5.8, 12.0) 7.7 (4.2, 12.0) 0.08
Median age (q1, q3) 60 (54, 67) 59 (55, 71) 0.65
Race
 White 95 (66) 26 (72) 0.51
 Other 48 (34) 10 (28)  
KPS
 80–100 105 (73) 29 (81) 0.38
 50–70 38 (27) 7 (19)  
Primary Site
 Lung 75 (52) 22 (61) 0.35
 Other 68 (48) 14 (39)  
Histology
 Renal cell 9 (6.3) 3(8.3) < 0.001
 Melanoma 3 (2.1) 7 (19.5)  
 Squamous cell 11(7.7) 6 (16.7)  
 Adenocarcinoma 91 (63.6) 17 (47.2)  
 Other 29 (20.3) 3 (8.3)  
Active Extra-CNS Disease 0.36
 Extensive 62 (43) 20 (56)  
 Bone only 8 (6) 3 (8)  
 Primary only 41 (29) 9 (25)  
 None 32 (22) 4 (11)  
Prior WBRT 0.01
 Yes 49 (34) 4 (11)  
 No 94 (66) 32 (89)  
Variables by lesion SRS alone (%) N = 286 SRS-ICI (%) N = 99 P-value
Tumor size 0.03
  ≤ 2 cm 226 (79) 88 (89)  
  > 2 cm 60 (21) 11 (11)  
SRS fractions
 Single fraction 203 (71) 77 (78) 0.19
 Multi-fraction 83 (29) 22 (22)  
Surgical Resection
 No 265 (93) 93 (94) 0.67
 Yes 21 (7) 6 (6)  
Concurrent Systemic therapy 0.007
 Yes 68 (24) 11 (11)  
 No 218 (76) 88 (89)  
Prior WBRT 0.004
 Yes 108 (37.8) 22 (22.2)  
 No 178 (62.2) 77 (77.8)  
Histology < 0.001
 Renal cell 14 (4.9) 15 (15.1)  
 Melanoma 12 (4.2) 20 (20.2)  
 Squamous cell 18 (6.3) 10 (10.1)  
 Adenocarcinoma 185 (64.7) 48 (48.5)  
 Other 57 (19.9) 6 (6.1)  
Median Prescription Dose for SRS (single fraction) 21 (20, 24) 24 (21, 24) < 0.001
Median Biologically Equivalent Dose for SRT (multiple fraction) 38 (36, 43) 50 (38, 51) 0.002